NeuroPace Inc

NeuroPace insider buying, RNS System RCT success, fast‑track FDA status and OCD pipeline promise a safe, effective neuromodulation future for refractory epilepsy.

NeuroPace insider buys: CMO Martha’s 5,460 RSUs and 14,550 zero‑cost options signal executive confidence and a potential upside for undervalued shares.

Insider selling at NeuroPace raises questions about future growth; yet its RNS epilepsy system remains proven and the company pushes into movement‑disorder trials, regulatory approvals and reimbursement plans to secure long‑term market strength.

NeuroPace insider buys: Non‑employee director Lacob Joseph purchases 865 shares at $13.00, boosting holdings to 14,754 amid price volatility and mixed executive sales—signaling cautious confidence in future growth.

NeuroPace insider selling signals cautious confidence: CMO and CEO offload shares amid price dips, negative earnings and volatile market—investors weigh rebalancing vs. risk.